Key result
Astragaloside IV improves cognitive function in heart failure rats by inhibiting the RAGE-ERK1/2-NF-κB pathway.
Why the study?
Cognitive impairment is prevalent in heart failure without effective pharmacological interventions, and the effect of Astragaloside IV on post-heart failure cognitive impairment had not been studied.
Does Astragaloside IV improve cognitive impairment in male rats with heart failure?
Does Astragaloside IV improve cognitive impairment in male rats with heart failure?
Answers are grounded in this paper and cite their sources.
Astragaloside IV improves cognitive function and cardiac structure in a rat model of heart failure by inhibiting the RAGE-ERK1/2-NF-κB inflammatory pathway.
Background and Purpose Cognitive impairment (CI) is prevalent in clinical patients with heart failure (HF). However, there are no effective pharmacological interventions for CI treatment. Astragaloside IV (AS‐IV) is the principal constituent of Astragalus Radix and effective in HF, but its action on CI after HF has not yet been studied. Experimental Approach Cognitive function was evaluated in behavioural experiments on male rats with HF. Transcriptomics and network pharmacology were used to identify potential pathways. Western blots, quantitative real‐time polymerase chain reaction (qRT‐PCR), Elisa, and electron microscopy were used to validate changes in identified pathways, brain inflammatory cytokines, postsynaptic membrane glutamate receptors and levels of apoptosis. Molecular docking and molecular dynamics simulation confirmed the binding ability of AS‐IV and selected core proteins. Key Results AS‐IV improved cardiac function and disordered cardiac muscle structure in rats with HF. The advanced glycation end‐products–receptor of advanced glycation end‐products (AGE–RAGE) signalling pathway was the core pathway. AS‐IV reduced the expression levels of RAGE, extracellular regulated protein kinases 1/2 (ERK1/2) and nuclear factor kappa‐B (NF‐ κ B). AS‐IV also attenuated the expression of proinflammatory factors, increased the levels of anti‐inflammatory factors, and up‐regulated postsynaptic membrane glutamate receptor expression. Molecular docking and molecular dynamics simulation showed that AS‐IV had favourable binding energy with RAGE. Conclusion and Implications AS‐IV enhances cognitive function of HF rats by inhibiting the RAGE–ERK1/2–NF‐ κ B signalling pathway to reduce inflammation and apoptosis and thereby improve synaptic function. AS‐IV emerges as a promising candidate for the prevention and treatment of HF‐CI.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2026) studied this question. Astragaloside IV improved cognitive function in heart failure rats by inhibiting the RAGE–ERK1/2–NF-κB pathway, reducing inflammation and apoptosis.
Synapse has enriched 10 related papers. Consider them for comparative context: